296 related articles for article (PubMed ID: 28609363)
1. O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors.
Raj N; Klimstra DS; Horvat N; Zhang L; Chou JF; Capanu M; Basturk O; Do RKG; Allen PJ; Reidy-Lagunes D
Pancreas; 2017 Jul; 46(6):758-763. PubMed ID: 28609363
[TBL] [Abstract][Full Text] [Related]
2. Short article: Evaluation of O6-methylguanine-DNA methyltransferase as a predicting factor of response to temozolomide-based chemotherapy in well-differentiated metastatic pancreatic neuroendocrine tumors.
Girot P; Dumars C; Mosnier JF; Muzellec L; Senellart H; Foubert F; Caroli-Bosc FX; Cauchin E; Regenet N; Matysiak-Budnik T; Touchefeu Y
Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):826-830. PubMed ID: 28328619
[TBL] [Abstract][Full Text] [Related]
3. MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors.
Cros J; Hentic O; Rebours V; Zappa M; Gille N; Theou-Anton N; Vernerey D; Maire F; Lévy P; Bedossa P; Paradis V; Hammel P; Ruszniewski P; Couvelard A
Endocr Relat Cancer; 2016 Aug; 23(8):625-33. PubMed ID: 27353036
[TBL] [Abstract][Full Text] [Related]
4. O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma.
Sonoda Y; Yokosawa M; Saito R; Kanamori M; Yamashita Y; Kumabe T; Watanabe M; Tominaga T
Int J Clin Oncol; 2010 Aug; 15(4):352-8. PubMed ID: 20232102
[TBL] [Abstract][Full Text] [Related]
5. O6-methylguanine-DNA methyltransferase (MGMT) status in neuroendocrine tumors: a randomized phase II study (MGMT-NET).
Lemelin A; Barritault M; Hervieu V; Payen L; Péron J; Couvelard A; Cros J; Scoazec JY; Bin S; Villeneuve L; Lombard-Bohas C; Walter T;
Dig Liver Dis; 2019 Apr; 51(4):595-599. PubMed ID: 30824408
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and predictive roles of MGMT protein expression and promoter methylation in sporadic pancreatic neuroendocrine neoplasms.
Schmitt AM; Pavel M; Rudolph T; Dawson H; Blank A; Komminoth P; Vassella E; Perren A
Neuroendocrinology; 2014; 100(1):35-44. PubMed ID: 25012122
[TBL] [Abstract][Full Text] [Related]
7. Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer.
Amatu A; Sartore-Bianchi A; Moutinho C; Belotti A; Bencardino K; Chirico G; Cassingena A; Rusconi F; Esposito A; Nichelatti M; Esteller M; Siena S
Clin Cancer Res; 2013 Apr; 19(8):2265-72. PubMed ID: 23422094
[TBL] [Abstract][Full Text] [Related]
8. Association between MGMT status and response to alkylating agents in patients with neuroendocrine neoplasms: a systematic review and meta-analysis.
Qi Z; Tan H
Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32141507
[TBL] [Abstract][Full Text] [Related]
9. Impact of Therapy Sequence with Alkylating Agents and MGMT Status in Patients with Advanced Neuroendocrine Tumors.
Krug S; Boch M; Rexin P; Gress TM; Michl P; Rinke A
Anticancer Res; 2017 May; 37(5):2491-2500. PubMed ID: 28476818
[TBL] [Abstract][Full Text] [Related]
10. Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study.
Campana D; Walter T; Pusceddu S; Gelsomino F; Graillot E; Prinzi N; Spallanzani A; Fiorentino M; Barritault M; Dall'Olio F; Brighi N; Biasco G
Endocrine; 2018 Jun; 60(3):490-498. PubMed ID: 29150792
[TBL] [Abstract][Full Text] [Related]
11. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.
Kulke MH; Hornick JL; Frauenhoffer C; Hooshmand S; Ryan DP; Enzinger PC; Meyerhardt JA; Clark JW; Stuart K; Fuchs CS; Redston MS
Clin Cancer Res; 2009 Jan; 15(1):338-45. PubMed ID: 19118063
[TBL] [Abstract][Full Text] [Related]
12. Clinical and in vitro studies of the correlation between MGMT and the effect of streptozocin in pancreatic NET.
Hijioka S; Sakuma K; Aoki M; Mizuno N; Kuwahara T; Okuno N; Hara K; Yatabe Y
Cancer Chemother Pharmacol; 2019 Jan; 83(1):43-52. PubMed ID: 30310970
[TBL] [Abstract][Full Text] [Related]
13. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
[TBL] [Abstract][Full Text] [Related]
14. Careful exclusion of non-neoplastic brain components is required for an appropriate evaluation of O6-methylguanine-DNA methyltransferase status in glioma: relationship between immunohistochemistry and methylation analysis.
Sasai K; Nodagashira M; Nishihara H; Aoyanagi E; Wang L; Katoh M; Murata J; Ozaki Y; Ito T; Fujimoto S; Kaneko S; Nagashima K; Tanaka S
Am J Surg Pathol; 2008 Aug; 32(8):1220-7. PubMed ID: 18580490
[TBL] [Abstract][Full Text] [Related]
15. Expression of O(6)-methylguanine DNA methyltransferase (MGMT) and its clinical significance in gastroenteropancreatic neuroendocrine neoplasm.
Yang QC; Wang YH; Lin Y; Xue L; Chen YJ; Chen MH; Chen J
Int J Clin Exp Pathol; 2014; 7(7):4204-12. PubMed ID: 25120800
[TBL] [Abstract][Full Text] [Related]
16. Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review).
Cabrini G; Fabbri E; Lo Nigro C; Dechecchi MC; Gambari R
Int J Oncol; 2015 Aug; 47(2):417-28. PubMed ID: 26035292
[TBL] [Abstract][Full Text] [Related]
17. The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients' survival: a meta-analysis.
Zhao H; Wang S; Song C; Zha Y; Li L
World J Surg Oncol; 2016 Oct; 14(1):261. PubMed ID: 27733166
[TBL] [Abstract][Full Text] [Related]
18. Expression and methylation status of MMR and MGMT in well-differentiated pancreatic neuroendocrine tumors and potential clinical applications.
Ban X; Mo S; Lu Z; Jia C; Shao H; Chang X; Mao X; Zhang Y; Pang J; Zhang Y; Yu S; Chen J
Endocrine; 2022 Sep; 77(3):538-545. PubMed ID: 35708896
[TBL] [Abstract][Full Text] [Related]
19. O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agents.
Walter T; van Brakel B; Vercherat C; Hervieu V; Forestier J; Chayvialle JA; Molin Y; Lombard-Bohas C; Joly MO; Scoazec JY
Br J Cancer; 2015 Feb; 112(3):523-31. PubMed ID: 25584486
[TBL] [Abstract][Full Text] [Related]
20. Temozolomide Treatment for Pediatric Refractory Anaplastic Ependymoma with Low MGMT Protein Expression.
Komori K; Yanagisawa R; Miyairi Y; Sakashita K; Shiohara M; Fujihara I; Morita D; Nakamura T; Ogiso Y; Sano K; Shirahata M; Fukuoka K; Ichimura K; Shigeta H
Pediatr Blood Cancer; 2016 Jan; 63(1):152-5. PubMed ID: 26305586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
